CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 205 enrolled
Drug / intervention
Losartan +1 moredrug
Likely dose
Losartan 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04312009
NCT04312009Phase 2Completed
CompareCT.gov

Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization

University of Minnesota·interventional·Posted Mar 17, 2020·Updated Jun 29, 2022

In Brief

A Phase 2 clinical trial evaluating Losartan and Placebo for Corona Virus Infection and 2 related conditions. Completed, enrolled 205 participants across 13 sites.

Detailed Summary

This is a multi-center, double-blinded study of COVID-19 infected patients requiring inpatient hospital admission randomized 1:1 to daily Losartan or placebo for 7 days or hospital discharge.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCorona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
CountriesUnited States
CollaboratorsBill and Melinda Gates Foundation

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedMar 17, 2020
Enrollment StartApr 13, 2020
Primary CompletionFeb 1, 2021
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 6.3 years ago

Interventions

Losartandrug

Losartan; 50 mg daily; oral administration

Placeboother

Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration